XRTX
XORTX Therapeutics Inc (XRTX)
Healthcare • NASDAQ • $2.79+5.28%
- Symbol
- XRTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.79
- Daily Change
- +5.28%
- Market Cap
- $4.32M
- Trailing P/E
- N/A
- Forward P/E
- 3.48
- 52W High
- $7.05
- 52W Low
- $1.73
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.22
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Company websiteResearch XRTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.